Financial Performance - For the six months ended June 30, 2022, the group recorded revenue of approximately RMB 30,299,000, a decrease of about 37.00% compared to RMB 48,093,000 for the same period in 2021[4] - The group reported a profit before tax of approximately RMB 19,117,000, down approximately 31.67% from RMB 27,977,000 in the same period of 2021[5] - Basic earnings per share for the six months ended June 30, 2022, were approximately RMB 1.63 cents, a decrease of about 30.04% from RMB 2.33 cents in the same period of 2021[5] - The net profit for the six months ended June 30, 2022, was RMB 16,249,000, compared to RMB 23,188,000 for the same period in 2021, representing a decrease of approximately 30%[28] - The income tax expense for the six months ended June 30, 2022, was RMB 2,867,000, compared to RMB 4,789,000 for the same period in 2021[30] Dividends - The board of directors recommended not to declare any dividend for the six months ended June 30, 2022[6] - The company did not recommend any dividend payment for the period, consistent with the previous year[31] - The board does not recommend the distribution of dividends for the six months ended June 30, 2022, consistent with the previous year[57] Cash Flow and Assets - The net cash generated from operating activities was RMB 716,000, compared to a net cash outflow of RMB 2,344,000 in the same period of 2021[16] - Total assets less current liabilities amounted to RMB 171,821,000 as of June 30, 2022, compared to RMB 155,572,000 as of December 31, 2021[14] - The group’s cash and cash equivalents decreased to RMB 7,086,000 from RMB 11,364,000 at the beginning of the period[16] - Trade receivables increased to RMB 142,759,000 as of June 30, 2022, from RMB 128,513,000 as of December 31, 2021[14] - As of June 30, 2022, the group's net current assets and net assets were approximately RMB 170,380,000 and RMB 171,821,000, respectively, compared to RMB 154,022,000 and RMB 155,572,000 as of December 31, 2021[55] Expenses - The group’s administrative expenses for the six months ended June 30, 2022, were RMB 821,000, down from RMB 5,853,000 in the same period of 2021[12] - The total administrative expenses and employee costs for the current period were approximately RMB 3,646,000, significantly lower than RMB 10,617,000 in the same period last year[54] Business Operations - The company is focused on providing integrated pharmaceutical services in China, including clinical research and post-market surveillance[20] - The company aims to become a comprehensive service provider under an internet framework in the healthcare sector[20] - The company established a biobanking laboratory to support clinical research, particularly for antiviral drug studies[46] - The company launched two new business models: RWS-Therapy and D-CRCO, aimed at redefining research-based treatment and commercialization in the digital healthcare era[47] - The company has formed partnerships with top medical institutions in cities like Beijing, Shanghai, and Guangzhou to enhance its digital healthcare services[48] Share Options and Governance - The stock option plan was approved on June 30, 2015, with a validity of 10 years[93] - The maximum number of shares available for subscription under the stock option plan is limited to 30% of the issued shares[100] - The total number of shares available for issuance under the share option plan is 78,087,166 shares, accounting for 7.85% of the total issued shares as of the interim report date[103] - The company has not granted, exercised, canceled, or allowed any other share options to lapse during the reporting period, aside from those mentioned[114] - The company has not appointed a CEO, and daily management is handled by executive directors and senior management[118] - The company complied with the corporate governance code during the reporting period, with exceptions noted regarding the separation of roles between the chairman and CEO[118] Market and Risk Management - The group closely monitors foreign currency risks and will hedge as necessary, with most transactions denominated in RMB[68] - The group continues to enhance its market promotion capabilities and expand its market network, focusing on value chain products in the local market[56] Employee Information - The total number of employees decreased from 50 as of December 31, 2021, to 44 as of June 30, 2022, with total employee and director remuneration approximately RMB 2,825,000, down from RMB 4,764,000 in the previous year[76]
中国医疗集团(08225) - 2022 - 中期财报